This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

RIM: Analysts' Upgrades, Downgrades

Editor's Note: Green and red arrows refer to intraday stock price movement.


AK Steel (AKS - Get Report) downgraded at Goldman from Buy to Neutral. Company is facing higher input costs.

The Buckle (BKE - Get Report) upgraded at Goldman from Sell to Neutral. $28 price target. Fashion cycle is easing for the company.

Corrections Corp of America (CXW - Get Report) downgraded at Barclays to Equal Weight from Overweight. Minimal margin improvement opportunities. Price target raised by a dollar to $28.

Ruddick (RDK) downgraded at BMO from Outperform to Market Perform. Valuation call, based on a $38 price target.

Research in Motion (RIMM) downgraded at Kaufman from Buy to Hold. $60 price target. Company is facing increased competition.

Rovi (ROVI) rated new Outperform at BMO. Coverage of ROVI was started with an Outperform rating. $60 price target. Growth should accelerate as its content and reach expands.

Reliance Steel (RS) upgraded at Goldman from Neutral to Buy. Company has exposure to growth in the aerospace and energy markets.

Seattle Genetics (SGEN - Get Report) rated new Overweight at Piper Jaffray. $20 price target. Company is on the verge of bringing its first drug to market.

Symantec (SYMC - Get Report) upgraded at ISI from Hold to Buy. $22 price target. Company is executing better and is a potential takeover target.

Taleo (TLEO) downgraded at Credit Suisse to Neutral from Outperform. Valuation call. Maintain $30 price target.

Trinity Industries (TRN) rated new Outperform at Wells Fargo. Rail supply industry appears to be at the beginning of a multi-year recovery.

Viropharma (VPHM) rated new Overweight at Piper Jaffray. $20 price target. HAE drug should ultimately be able to generate $500 million of annual U.S. sales.

This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AKS $4.42 -0.90%
BKE $50.30 1.15%
CXW $39.89 0.45%
SGEN $36.25 -0.49%
SYMC $25.16 0.44%


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs